Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2021-03-10 Capital/Financing Update
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common shares and pre-funded warrants by Xenon Pharmaceuticals Inc. It includes detailed offering terms, underwriting information, risk factors, use of proceeds, and other related disclosures typical of a securities offering document. The presence of registration numbers, underwriting discounts, and offering prices confirms this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or a brief summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2021-03-10 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an underwriting agreement for a public offering of common shares and pre-funded warrants, including details about the offering price, number of shares, and legal opinions. There are no financial statements or comprehensive financial data presented, only an announcement of a financing event. This fits the category of a Capital/Financing Update (CAP) rather than a full financial report or earnings release. The document length is 8515 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion. Therefore, the correct classification is CAP with high confidence.
2021-03-10 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to an offering of common shares and pre-funded warrants by Xenon Pharmaceuticals Inc. It is filed pursuant to Rule 424(b)(5) under the Securities Act, which is a form used for prospectus supplements related to securities offerings. The text includes detailed information about the offering terms, risk factors, use of proceeds, underwriting, and legal matters, typical of a capital raising document. There is no indication that this is a financial report, earnings release, or any other type of regulatory filing. The document is clearly about a financing activity, specifically a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, supporting a high confidence level.
2021-03-09 English
10-K
Annual Report FY 2020
2021-03-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes an Item 2.02 about results of operations and financial condition, but it states that the financial results are announced via a press release attached as an exhibit and that the information is furnished but not filed. It also includes Item 5.02 about departure of a director/officer. The document is short (3877 characters) and primarily serves as a notification of events rather than a full financial report. It does not contain detailed financial statements or substantive financial data itself. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-03-01 English
FORM 4 SUBMISSION
Director's Dealing
2021-02-18 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.